
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
Changing Landscapes: A Special Report on the World?s Top 50 Pharma Companies
over 20 years ago
More Than a Game of Keep Awayover 20 years ago
Teamsters v. Pfizerover 20 years ago
Leadership: It is Personalover 20 years ago
Legal: The Kickback Effectover 20 years ago
Washington Report: Opportunity Knocksover 20 years ago
From the Editor: Mixed Signalsover 20 years ago
Medicare Part D: D for Doomed?over 20 years ago
Thought Leader: Scientific Expressionover 20 years ago
Opinion: Brussels Sproutsover 20 years ago
Global Report: A Hope and a Payer




